Skip to main content
      Cooper et al. FAERS based analysis of adverse events with avacopan.3658 patients on avacopan, 30 million overall. DILI s

      Richard Conway RichardPAConway

      1 week 1 day ago
      Cooper et al. FAERS based analysis of adverse events with avacopan.3658 patients on avacopan, 30 million overall. DILI seems to be the big concern, with Reporting Odds Ratio of >17. @RheumNow #ACR25 Abstr#2519 https://t.co/1LoDvRHkqa
      IgG4 - Rare but Rx

      Several studies #ACR25 @ACRheum were presented
      Outcome measures

      Rx
      #steroids

      #CD19 mAb #Inebiliz

      Janet Pope Janetbirdope

      1 week 1 day ago
      IgG4 - Rare but Rx Several studies #ACR25 @ACRheum were presented Outcome measures Rx #steroids #CD19 mAb #Inebilizumab 👍+RCT reduction of flares BTKi #Rilzabrutinib #Zanubrutinib #JAKi +RCT of #tofacitinib +steroids vs pred @ACRheum @RheumNow #ACR25 1163 LB02 0239 1172 https://t.co/xC3wgaN9bk
      Sjögren’s, decoded by Ab -->ESSDAI domains:
      • anti-SSA → glandular
      • anti-Ro52 / SCL70 → biologic activity

      Jiha Lee JihaRheum

      1 week 1 day ago
      Sjögren’s, decoded by Ab -->ESSDAI domains: • anti-SSA → glandular • anti-Ro52 / SCL70 → biologic activity • anti-nucleosome → pulmonary • anti-histone → pulmonary + cutaneous Distinct serologic–ESSDAI patterns may guide monitoring and management @RheumNow #ACR25 A#2295
      #ACR25 Abstr#LB14 Deep blood & tissue depletion are not just confined to CAR-T. Exploratory analysis of REGENCY show

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 week 1 day ago

      #ACR25 Abstr#LB14 Deep blood & tissue depletion are not just confined to CAR-T. Exploratory analysis of REGENCY showed Obinutuzumab induced near-complete depletion & significantly reduced plasma in kidney tissue vs PBO @RheumNow https://t.co/r1danWBM7D

      In PsA, a predictive model using routine labs (NLR, LMR, ESR, C3, baseline DAPSA) identified TNFi responders with 100% s

      Antoni Chan MD (Prof) synovialjoints

      1 week 1 day ago
      In PsA, a predictive model using routine labs (NLR, LMR, ESR, C3, baseline DAPSA) identified TNFi responders with 100% sensitivity and 0.861 AUC. Supports biomarker-driven personalization of PsA treatment. Abstract#2371 @RheumNow #ACR25 https://t.co/lojQFfWsJi
      Agrawal et al. Case study of tofacitinib + bDMARDs in refractory IA. 7 SpA, 2 RA, 1 JIA. Effective and safe. @RheumNow #

      Richard Conway RichardPAConway

      1 week 1 day ago
      Agrawal et al. Case study of tofacitinib + bDMARDs in refractory IA. 7 SpA, 2 RA, 1 JIA. Effective and safe. @RheumNow #ACR25 Abstr#2338 https://t.co/Y0B3W4csJX
      In RA, “strong bones” can give false reassurance.
      Pts with higher baseline BMD had faster bone loss, often tied to G

      Jiha Lee JihaRheum

      1 week 1 day ago
      In RA, “strong bones” can give false reassurance. Pts with higher baseline BMD had faster bone loss, often tied to GC use and less osteoporosis treatment. Undermanagement, not biology, may drive decline. @RheumNow #ACR25 Abstract#2244 https://t.co/N421ESAUy9
      After melanoma, should RA patients stop DMARDs?

      These VA data (n=644) showed no mortality signal, and trending to survi

      David Liew drdavidliew

      1 week 1 day ago
      After melanoma, should RA patients stop DMARDs? These VA data (n=644) showed no mortality signal, and trending to survival benefit with b/tsDMARDs Provisos over methotrexate, invasive disease etc, but don’t hold off treating the RA because of melanoma #ACR25 ABST2237 @RheumNow https://t.co/l9n1V6YVln
      #ACR25 Abstr#LB11 2025 belongs to Sjogren! In patients with ESSDAI=>5, a Phase 3 RCT of Telitacicept (BAFF/APRIL-i) i

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 week 1 day ago
      #ACR25 Abstr#LB11 2025 belongs to Sjogren! In patients with ESSDAI=>5, a Phase 3 RCT of Telitacicept (BAFF/APRIL-i) in China met primary endpoint; change in ESSDAI vs PBO. ESSPRI improved too! Wow! That PBO response was a flat line! Will need Global study @RheumNow #ACRBest https://t.co/LXxpBZPCtF
      #IL2 #Rx in active #SLE?
      Maybe 🤔

      IL2 is tricky - low dose May help #SLE but too much of a good thing may have a neg

      Janet Pope Janetbirdope

      1 week 1 day ago
      #IL2 #Rx in active #SLE? Maybe 🤔 IL2 is tricky - low dose May help #SLE but too much of a good thing may have a neg impact. RCT of IL2i in #SLE gave a good dose response and improved TRegs. #ACRBest #ACR25 @RheumNow @ACRheum #LB01 https://t.co/F61qz5x5We
      Can a Fitbit track RA?

      This Japanese clinic is using Fitbit data and have seen it correlate with CDAI across their RA c

      David Liew drdavidliew

      1 week 1 day ago
      Can a Fitbit track RA? This Japanese clinic is using Fitbit data and have seen it correlate with CDAI across their RA clinic. Maybe instead of asking about our patients mobility and sleep, we should be measuring it? #ACR25 ABST2253 @RheumNow https://t.co/rg2SKgn7K2
      #1751 In early RA, higher disease activity, inflammation & older age linked to more ILD changes on machine-learning

      Mrinalini Dey DrMiniDey

      1 week 1 day ago
      #1751 In early RA, higher disease activity, inflammation & older age linked to more ILD changes on machine-learning chest CT. Even subtle QCT abnormalities correlated with reduced lung function pointing to early inflammatory pathways in RA-ILD. @RheumNow #ACR25
      Are the clues of RA there in the EMR, before the diagnosis is made?

      Jina off-the-shelf AI with subsequent retraining fo

      David Liew drdavidliew

      1 week 1 day ago
      Are the clues of RA there in the EMR, before the diagnosis is made? Jina off-the-shelf AI with subsequent retraining found the digital fingerprint of RA in @MayoClinic medical notes, years before formal diagnosis. The clues are there #ACR25 ABST2260 @MyasoedovaElena @RheumNow https://t.co/onGlKUmefd
      Adverse events from avacopan the WHO pharmacovigilence database (VigiBase)

      Not a lot new - infections happen, hepatic e

      Mike Putman EBRheum

      1 week 1 day ago
      Adverse events from avacopan the WHO pharmacovigilence database (VigiBase) Not a lot new - infections happen, hepatic events happen but seem to be somewhat rare Pharmacovigilence is hard; most events go unreported & we often have the classic "denominator problem" (ie we saw https://t.co/28tYkXv0Lz
      ×